Strattera

Strattera Overdosage

atomoxetine

Manufacturer:

Eli Lilly

Distributor:

DKSH
Full Prescribing Info
Overdosage
During post-marketing, there have been no fatalities involving overdose with Strattera alone, including intentional overdose at amounts up to or exceeding 1500mg. The most commonly reported symptoms accompanying acute and chronic overdoses were gastrointestinal symptoms, somnolence, dizziness, tremor and abnormal behaviour. Hyperactivity and agitation have also been reported. Signs and symptoms consistent with mild to moderate sympathetic nervous system activation (e.g. tachycardia, blood pressure increased, mydriasis, dry mouth) were also observed. Most events were mild to moderate. In some cases of overdose involving Strattera, seizures and QT prolongation have been reported (see Pharmacology: Pharmacodynamics under Actions). There have also been reports of fatal, acute overdoses involving mixed ingestion of Strattera and at least one other drug. There is limited clinical trial experience with Strattera overdose.
No specific information is available on the treatment of overdose with Strattera. An airway should be established. Monitoring of cardiac and vital signs is recommended, along with appropriate symptomatic and supportive measures. Gastric lavage may be indicated if performed soon after ingestion. Activated charcoal may be useful in limiting absorption. Because Strattera is highly protein-bound, dialysis is not likely to be useful in the treatment of overdose.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in